A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures

PARP inhibitors are approved for the treatment of solid tumor types that frequently harbor alterations in the key homologous recombination (HR) genes, BRCA1/2. Other tumor types, such as lung cancer, may also be HR deficient, but the frequency of such cases is less well characterized. Specific DNA a...

Descripción completa

Detalles Bibliográficos
Autores principales: Diossy, Miklos, Sztupinszki, Zsofia, Borcsok, Judit, Krzystanek, Marcin, Tisza, Viktoria, Spisak, Sandor, Rusz, Orsolya, Timar, Jozsef, Csabai, István, Fillinger, Janos, Moldvay, Judit, Pedersen, Anders Gorm, Szuts, David, Szallasi, Zoltan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213828/
https://www.ncbi.nlm.nih.gov/pubmed/34145376
http://dx.doi.org/10.1038/s41698-021-00199-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213828/
https://www.ncbi.nlm.nih.gov/pubmed/34145376
http://dx.doi.org/10.1038/s41698-021-00199-8

Ejemplares similares